Evidence map›Paper›PMID 42376452›Full record

ArticleFrontiers in neurology2026

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-life mobility insights from wearable sensors.

Alessandro Zampogna, Luigi Borzì, Domiziana Rinaldi, Gabriele Imbalzano, Martina Patera, Marco Falletti, Carlo Alberto Artusi, Edoardo Bianchini, Leonardo Lopiano, Gabriella Olmo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandro Zampogna *Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Luigi Borzì *Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy.
Domiziana RinaldiDepartment of Neuroscience, Mental Health and Sense Organs (NESMOS), Sapienza University of Rome, Rome, Italy.
Gabriele ImbalzanoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Torino, Italy.
Martina PateraDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Marco FallettiDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Carlo Alberto ArtusiDepartment of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
Edoardo BianchiniFondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Leonardo LopianoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Torino, Italy.
Gabriella OlmoDepartment of Control and Computer Engineering, Politecnico di Torino, Turin, Italy.
Antonio SuppaDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale/objectives: In advanced Parkinson's disease (APD), the intermittent dopaminergic delivery of oral L-Dopa contributes to the occurrence of fluctuations and dyskinesia. Continuous dopaminergic delivery through intrajejunal L-Dopa/Carbidopa intestinal gel (LCIG) is an established therapeutic strategy to manage these motor complications, but its impact on real-life motor performances has never been characterised objectively. This cross-sectional pilot study used wearable sensors to quantitatively evaluate the impact of LCIG on patients' motor performance in real-world settings. Material/methods: Forty-three APD patients, including 15 treated with LCIG infusion (APD Results: Despite comparable clinical and demographic profiles, APD Discussion/conclusion: LCIG provides a more stable gait pattern than optimized oral dopaminergic therapy in appropriately selected APD patients, as captured by wearable sensors in real-world conditions. This likely reflects more consistent motor control throughout the day due to continuous dopaminergic delivery. By detecting fluctuation-related motor impairment through variability metrics, wearable sensor technology may offer a valuable tool to enhance the clinical management of LCIG, supporting patient selection, medication titration, and the longitudinal monitoring of treatment efficacy and safety.

Indexed as

fluctuationsLCIGmotor complicationsParkinson’s diseasewearable sensors

Identifiers

PMID42376452
PMCPMC13310742

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.